Treatment response and overall outcome of patients with relapsed and refractory peripheral T-cell lymphoma compared to diffuse large B-cell lymphoma

Noemi Puig, Lisa Wang, Tara Seshadri, Khalil Al-Farsi, Armand Keating, Michael Crump, John Kuruvilla

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The purpose of the study was to assess treatment response and overall outcome in a cohort of patients with relapsed and refractory peripheral T-cell lymphoma and to compare the results with those for patients with diffuse large B-cell lymphoma treated in a similar manner. We retrospectively analyzed data of 40 consecutive adult patients with relapsed and refractory peripheral T-cell lymphoma referred to our institution for consideration of second-line chemotherapy aiming for autologous stem cell transplant between January 1999 and December 2006. A cohort of 126 patients with diffuse large B-cell lymphoma managed similarly served as a comparison group. Most (≥ 75%) patients received ESHAP (etoposide, methylprednisolone, cytarabine, cisplatin) or DHAP (cisplatin, cytosine arabinoside, dexamethasone) as salvage chemotherapy. From first relapse/progression, overall survival at 2 years was 54% (95% confidence interval [CI]: 38-76) for the peripheral T-cell lymphoma cohort and 49% (95% CI: 39-60) for the diffuse large B-cell lymphoma cohort (p = 0.098). Overall response rate to salvage chemotherapy was similar between both groups (63% vs. 52%). Post-autologous stem cell transplant, 1-year progression-free survival was 20% (95% CI: 9-48) for patients with peripheral T-cell lymphoma and 47% (95% CI: 36-61) for patients with diffuse large B-cell lymphoma. Two-year overall survival post-autologous stem cell transplant was 43% (95% CI: 26-71) and 54% (95% CI: 43-68), respectively. Patients with relapsed and refractory peripheral T-cell lymphoma and diffuse large B-cell lymphoma showed a similar response to salvage chemotherapy and overall survival. Likely due to imbalances in risk factors at relapse, progression-free survival post-autologous stem cell transplant was inferior in the peripheral T-cell lymphoma group. Strategies aiming to maintain response duration post-autologous stem cell transplant could improve the outcome of patients with peripheral T-cell lymphoma.

Original languageEnglish
Pages (from-to)507-513
Number of pages7
JournalLeukemia and Lymphoma
Volume54
Issue number3
DOIs
Publication statusPublished - Mar 2013

Fingerprint

Peripheral T-Cell Lymphoma
Lymphoma, Large B-Cell, Diffuse
Confidence Intervals
Stem Cells
Transplants
Drug Therapy
Therapeutics
Cytarabine
Cisplatin
Disease-Free Survival
Survival
Recurrence
Methylprednisolone
Etoposide
Dexamethasone

Keywords

  • ASCT
  • PTCL
  • Refractory
  • Relapsed
  • Salvage

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Treatment response and overall outcome of patients with relapsed and refractory peripheral T-cell lymphoma compared to diffuse large B-cell lymphoma. / Puig, Noemi; Wang, Lisa; Seshadri, Tara; Al-Farsi, Khalil; Keating, Armand; Crump, Michael; Kuruvilla, John.

In: Leukemia and Lymphoma, Vol. 54, No. 3, 03.2013, p. 507-513.

Research output: Contribution to journalArticle

Puig, Noemi ; Wang, Lisa ; Seshadri, Tara ; Al-Farsi, Khalil ; Keating, Armand ; Crump, Michael ; Kuruvilla, John. / Treatment response and overall outcome of patients with relapsed and refractory peripheral T-cell lymphoma compared to diffuse large B-cell lymphoma. In: Leukemia and Lymphoma. 2013 ; Vol. 54, No. 3. pp. 507-513.
@article{7251c93852bf406a88a701c14593b5cf,
title = "Treatment response and overall outcome of patients with relapsed and refractory peripheral T-cell lymphoma compared to diffuse large B-cell lymphoma",
abstract = "The purpose of the study was to assess treatment response and overall outcome in a cohort of patients with relapsed and refractory peripheral T-cell lymphoma and to compare the results with those for patients with diffuse large B-cell lymphoma treated in a similar manner. We retrospectively analyzed data of 40 consecutive adult patients with relapsed and refractory peripheral T-cell lymphoma referred to our institution for consideration of second-line chemotherapy aiming for autologous stem cell transplant between January 1999 and December 2006. A cohort of 126 patients with diffuse large B-cell lymphoma managed similarly served as a comparison group. Most (≥ 75{\%}) patients received ESHAP (etoposide, methylprednisolone, cytarabine, cisplatin) or DHAP (cisplatin, cytosine arabinoside, dexamethasone) as salvage chemotherapy. From first relapse/progression, overall survival at 2 years was 54{\%} (95{\%} confidence interval [CI]: 38-76) for the peripheral T-cell lymphoma cohort and 49{\%} (95{\%} CI: 39-60) for the diffuse large B-cell lymphoma cohort (p = 0.098). Overall response rate to salvage chemotherapy was similar between both groups (63{\%} vs. 52{\%}). Post-autologous stem cell transplant, 1-year progression-free survival was 20{\%} (95{\%} CI: 9-48) for patients with peripheral T-cell lymphoma and 47{\%} (95{\%} CI: 36-61) for patients with diffuse large B-cell lymphoma. Two-year overall survival post-autologous stem cell transplant was 43{\%} (95{\%} CI: 26-71) and 54{\%} (95{\%} CI: 43-68), respectively. Patients with relapsed and refractory peripheral T-cell lymphoma and diffuse large B-cell lymphoma showed a similar response to salvage chemotherapy and overall survival. Likely due to imbalances in risk factors at relapse, progression-free survival post-autologous stem cell transplant was inferior in the peripheral T-cell lymphoma group. Strategies aiming to maintain response duration post-autologous stem cell transplant could improve the outcome of patients with peripheral T-cell lymphoma.",
keywords = "ASCT, PTCL, Refractory, Relapsed, Salvage",
author = "Noemi Puig and Lisa Wang and Tara Seshadri and Khalil Al-Farsi and Armand Keating and Michael Crump and John Kuruvilla",
year = "2013",
month = "3",
doi = "10.3109/10428194.2012.719615",
language = "English",
volume = "54",
pages = "507--513",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Treatment response and overall outcome of patients with relapsed and refractory peripheral T-cell lymphoma compared to diffuse large B-cell lymphoma

AU - Puig, Noemi

AU - Wang, Lisa

AU - Seshadri, Tara

AU - Al-Farsi, Khalil

AU - Keating, Armand

AU - Crump, Michael

AU - Kuruvilla, John

PY - 2013/3

Y1 - 2013/3

N2 - The purpose of the study was to assess treatment response and overall outcome in a cohort of patients with relapsed and refractory peripheral T-cell lymphoma and to compare the results with those for patients with diffuse large B-cell lymphoma treated in a similar manner. We retrospectively analyzed data of 40 consecutive adult patients with relapsed and refractory peripheral T-cell lymphoma referred to our institution for consideration of second-line chemotherapy aiming for autologous stem cell transplant between January 1999 and December 2006. A cohort of 126 patients with diffuse large B-cell lymphoma managed similarly served as a comparison group. Most (≥ 75%) patients received ESHAP (etoposide, methylprednisolone, cytarabine, cisplatin) or DHAP (cisplatin, cytosine arabinoside, dexamethasone) as salvage chemotherapy. From first relapse/progression, overall survival at 2 years was 54% (95% confidence interval [CI]: 38-76) for the peripheral T-cell lymphoma cohort and 49% (95% CI: 39-60) for the diffuse large B-cell lymphoma cohort (p = 0.098). Overall response rate to salvage chemotherapy was similar between both groups (63% vs. 52%). Post-autologous stem cell transplant, 1-year progression-free survival was 20% (95% CI: 9-48) for patients with peripheral T-cell lymphoma and 47% (95% CI: 36-61) for patients with diffuse large B-cell lymphoma. Two-year overall survival post-autologous stem cell transplant was 43% (95% CI: 26-71) and 54% (95% CI: 43-68), respectively. Patients with relapsed and refractory peripheral T-cell lymphoma and diffuse large B-cell lymphoma showed a similar response to salvage chemotherapy and overall survival. Likely due to imbalances in risk factors at relapse, progression-free survival post-autologous stem cell transplant was inferior in the peripheral T-cell lymphoma group. Strategies aiming to maintain response duration post-autologous stem cell transplant could improve the outcome of patients with peripheral T-cell lymphoma.

AB - The purpose of the study was to assess treatment response and overall outcome in a cohort of patients with relapsed and refractory peripheral T-cell lymphoma and to compare the results with those for patients with diffuse large B-cell lymphoma treated in a similar manner. We retrospectively analyzed data of 40 consecutive adult patients with relapsed and refractory peripheral T-cell lymphoma referred to our institution for consideration of second-line chemotherapy aiming for autologous stem cell transplant between January 1999 and December 2006. A cohort of 126 patients with diffuse large B-cell lymphoma managed similarly served as a comparison group. Most (≥ 75%) patients received ESHAP (etoposide, methylprednisolone, cytarabine, cisplatin) or DHAP (cisplatin, cytosine arabinoside, dexamethasone) as salvage chemotherapy. From first relapse/progression, overall survival at 2 years was 54% (95% confidence interval [CI]: 38-76) for the peripheral T-cell lymphoma cohort and 49% (95% CI: 39-60) for the diffuse large B-cell lymphoma cohort (p = 0.098). Overall response rate to salvage chemotherapy was similar between both groups (63% vs. 52%). Post-autologous stem cell transplant, 1-year progression-free survival was 20% (95% CI: 9-48) for patients with peripheral T-cell lymphoma and 47% (95% CI: 36-61) for patients with diffuse large B-cell lymphoma. Two-year overall survival post-autologous stem cell transplant was 43% (95% CI: 26-71) and 54% (95% CI: 43-68), respectively. Patients with relapsed and refractory peripheral T-cell lymphoma and diffuse large B-cell lymphoma showed a similar response to salvage chemotherapy and overall survival. Likely due to imbalances in risk factors at relapse, progression-free survival post-autologous stem cell transplant was inferior in the peripheral T-cell lymphoma group. Strategies aiming to maintain response duration post-autologous stem cell transplant could improve the outcome of patients with peripheral T-cell lymphoma.

KW - ASCT

KW - PTCL

KW - Refractory

KW - Relapsed

KW - Salvage

UR - http://www.scopus.com/inward/record.url?scp=84873330937&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873330937&partnerID=8YFLogxK

U2 - 10.3109/10428194.2012.719615

DO - 10.3109/10428194.2012.719615

M3 - Article

VL - 54

SP - 507

EP - 513

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 3

ER -